Search This Blog

Thursday, May 7, 2026

Amylyx completes Phase 3 LUCIDITY enrollment, starts U.S. expanded access program for avexitide

 

Amylyx completes Phase 3 LUCIDITY enrollment, starts U.S. expanded access program for avexitide in post-bariatric hypoglycemia

  • Amylyx Pharmaceuticals reported Q1 2026 net loss of $41.3 million.
  • Ended Q1 2026 with $279.8 million in cash and an expected runway into 2028.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)